HGV 0.00% 4.1¢ hygrovest limited

Good news for sufferers of MS. MMJ RECEIVES APPROVAL TO CONDUCT...

  1. 7,830 Posts.
    lightbulb Created with Sketch. 4
    Good news for sufferers of MS.

    MMJ RECEIVES APPROVAL TO CONDUCT PHASE 2 CLINICAL TRIAL FOR TREATMENT OF MULTIPLE SCLEROSIS SYMPTOMS Highlights: • 100%-owned subsidiary, PhytoTech Therapeutics, receives Clinical Site and Ministry of Health approvals to conduct Phase 2 clinical trial of PTL201 • Phase 2 clinical trial is aimed at measuring safety and efficacy of the PTL201 capsules in treating spasticity related symptoms in multiple sclerosis (MS) patients • Phase 2 clinical trial is double-blind, randomised, placebo-controlled, parallel-group study in 70 MS patients • Success of Phase 2 will be a major step towards commercial development of the PTL201 drug for treatment of MS debilitating symptoms • Phase 2 clinical trial of PTL101 to treat refractory epilepsy in paediatric patients is proceeding as planned
 
watchlist Created with Sketch. Add HGV (ASX) to my watchlist
(20min delay)
Last
4.1¢
Change
0.000(0.00%)
Mkt cap ! $8.622M
Open High Low Value Volume
4.1¢ 4.1¢ 4.1¢ $1.652K 40.30K

Buyers (Bids)

No. Vol. Price($)
2 291807 4.1¢
 

Sellers (Offers)

Price($) Vol. No.
4.2¢ 26115 1
View Market Depth
Last trade - 10.04am 24/07/2024 (20 minute delay) ?
HGV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.